Intralymphatic administration of BCG in melanoma patients

Natale Cascinelli, Gian Paolo Balzarini, Vincenzo Fontana, Sergio Orefice, Umberto Veronesi

Research output: Contribution to journalArticlepeer-review


From November 1973 to December 1974, 20 patients with advanced malignant melanoma were treated with BCG given by intralymphatic route at the Cancer Institute of Milan. The lyophilized Pasteur BCG was used. Patients were treated with a single dose ranging from 0.2-80 mg. Patients' performance status was never severely impaired. The most frequent side effects were fever, lymphangitis, and lymph node enlargement. Variations were observed in white cell count, ERS and immunoglobulins; in no case did we find evidence of liver toxicity or tumor growth enhancement. It is concluded that the intralymphatic route is a safe way of administrating BCG.

Original languageEnglish
Pages (from-to)157-161
Number of pages5
JournalCancer Immunology, Immunotherapy
Issue number3
Publication statusPublished - 1977

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology


Dive into the research topics of 'Intralymphatic administration of BCG in melanoma patients'. Together they form a unique fingerprint.

Cite this